Duration of adjuvant chemotherapy for patients with advanced CRC is indefinite, altered by either disease progression or treatment intolerability. Deflexifol addresses the issue of treatment tolerability. Deflexifol offers the following competitive advantages over existing “standard of care” anti-metabolite regimens:
• Reduction of common adverse events such as neuropathic pain, venous inflammation, catheter blockage and sepsis;
• Simultaneous administration of all active ingredients;
• Significantly reduced time of administration; and
• Scalable manufacture and low cost of goods.
Deflexifol provides potential for delivery of a “well-tolerated” 5-FU/LV chemotherapy as a single injection formulation. Deflexifol could replace the standard 5FU in all regimens using 5FU or capecitabine in the appropriate tumor types such as colon, breast, head and neck and pancreas.
A lower incidence of adverse events during adjuvant chemotherapy would lead to improved patient outcomes via lower levels of treatment interruption and discontinuation. Treatment times would be reduced.
The following rabbit ear model shows that Deflexifol reduces symptoms of phlebitis.